Metacrine, Inc.

📍 San Diego, United States🗓 Founded 2014👥 4 employees💰 Last funded Jun 2016
Biotechnology Research🌐 metacrine.com
Website LinkedIn
Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases. Our most advanced programs target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis (NASH), a liver disease that affects 17 million people in the U.S. and is characterized by excess liver fat, inflammation and fibrosis. We believe that potency and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds, and have selected two oral FXR candidates from a unique chemical scaffold, MET409 and MET642. With our platform, we believe we can develop differentiated FXR agonist therapies for liver and GI diseases.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Metacrine, Inc.?
Metacrine, Inc. has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Metacrine, Inc. last raise funding?
The most recent investment in Metacrine, Inc. recorded on gritt.io was in June 2016.
When was Metacrine, Inc. founded?
Metacrine, Inc. was founded in 2014.
What industry is Metacrine, Inc. in?
Metacrine, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Metacrine, Inc. based?
Metacrine, Inc. is headquartered in San Diego, United States.